| abstract |
An anti-KIR antibody comprising the CDR1, CDR2 and CDR3 domains in a heavy chain variable region having the sequence set forth in SEQ ID NO: 3, and the CDR1, CDR2 and CDR3 domains in a light chain variable region having the sequence set forth in SEQ ID NO: 5, and an anti-PD-1 antibody comprising the domains CDR1, CDR2 and CDR3 in a variable region of the heavy chain having the sequence set forth in SEQ ID NO: 19, and the CDR1, CDR2 and CDR3 domains in a variable region of the light chain having the sequence set forth in SEQ ID NO: 21, for use in a method for the treatment of cancer in a human patient, wherein the method comprises at least an administration cycle, in which the cycle is a period of eight weeks, in which for each of the at least one cycle, two doses of the anti-KIR antibody are administered at a dose of 0.1, 0.3 , 1, 3, 6 or 10 mg / kg and four doses of the anti-PD-1 antibody are administered at a dose of 3 mg / kg. |